Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
In preclinical experiments [212Pb] VMT01 demonstrated efficacy via direct cell killing at high radiation doses and through immunostimulatory low-dose induction of immune-mediated cell death.Perspective Therapeutics, Inc. (NYSE: CATX) is down 13% at $11.53 at last check Friday.
賽諾菲安萬特公司（紐交所：CATX）週五最新數據顯示下跌13%，報11.53美元。
The downtrend comes as initial results from its study of [212Pb]VMT01 are set to be presented to the International Congress of the Society for Melanoma Research.
這種下行趨勢發生在其[212Pb]VMT01研究的初步結果即將提交給國際黑色素瘤研究學會大會的時候。
VMT01 is a MC1R-targeted radiopharmaceutical therapy (RPT) that can be radiolabeled with either 203Pb for patient selection and dosimetry assessments or 212Pb for alpha particle therapy.
VMT01 是一種MC1R靶向的放射性藥物療法（RPT），可以用203Pb進行患者選擇和劑量評估，也可以用212Pb進行α粒子療法。
In preclinical experiments [212Pb] VMT01 demonstrated efficacy via direct cell killing at high radiation doses and through immunostimulatory low-dose induction of immune-mediated cell death.
在臨床前實驗中，[212Pb] VMT01 在高輻射劑量下通過直接擊殺細胞和通過免疫刺激低劑量誘導免疫介導的細胞死亡展現出療效。
Efficacy was augmented by immune checkpoint inhibitors (ICIs).
免疫檢查點抑制劑（ICIs）增強了療效。
Three patients were enrolled in Cohort 1, while seven were enrolled in Cohort 2.
第一隊有三名患者，而第二隊有七名患者參加。
Patients in each cohort received a median of five prior lines of systematic therapy.
每個隊的患者平均接受了五種先前系統治療。
- No dose-limiting toxicities were observed among any patients, and no adverse events led to treatment discontinuation. Treatment-emergent adverse events (TEAEs) were mostly Grades 1 and 2; there were no Grade 4 or 5 TEAEs.
- No renal toxicities have been reported to date.
- All patients in Cohort 1 completed three treatments, with one patient experiencing a RECIST version 1.1 objective response and two patients experiencing stable disease at nine and 11 months from the start of treatment, respectively.
- In Cohort 2, patients progressed after either the first cycle (3 patients) or the second cycle (4 patients).
- 在任何患者中未觀察到劑量限制性毒性，並且沒有不良事件導致治療中止。治療相關的不良事件（TEAEs）主要是1級和2級；沒有4級或5級的TEAEs。
- 到目前爲止尚未報告腎毒性。
- 所有第1隊患者完成了三次治療，其中一名患者在治療開始後九個月和十一個月分別獲得了RECISt版本1.1的客觀治療反應，另外兩名患者保持疾病穩定。
- 在第2隊中，患者在第一週期（3名患者）或第二週期（4名患者）後出現了進展。
The Safety Monitoring Committee (SMC) has reviewed these findings. The SMC recommended exploring a lower dose level of 1.5 mCi per dose, which is lower than the dose administered in Cohort 1, both as a single agent and combined with the anti-PD-1 antibody, Bristol Myers Squibb & Co (NYSE:BMY) Opdivo (nivolumab).
安全監測委員會（SMC）已經審查了這些發現。SMC建議探索每劑1.5 mCi的更低劑量水平，該劑量低於在第1隊單藥和與抗PD-1抗體Bristol Myers Squibb& Co（紐交所:BMY）Opdivo（尼伐替尼）聯合使用時給予的劑量。
The SMC recommendation would allow for the monotherapy and combination cohorts to proceed concurrently.
SMC的建議將允許單獨治療和聯合隊同時進行。
An amendment to further explore lower dose levels for monotherapy is planned. The combination cohort at 1.5 mCi per dose with nivolumab is active and now open for enrollment.
計劃修訂以進一步探索單藥更低的劑量水平。每劑1.5 mCi的聯合隊與尼伐替尼目前已開始招募。
- World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice.
- 世界第三大場外交易參與者賽諾菲安萬特（Sanofi）的消費健康部門即將與Clayton Dubilier & Rice達成價值160億美元的交易。
